NCT00737841

Effect of Bifidobacterium on Irritable Bowel Syndrome

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Tohoku University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

There has been no data on effect of Bifidobacterium breve on symptoms of patients with irritable bowel syndrome (IBS). We hypothesized that Bifidobacterium breve is effective on symptoms of IBS patients.

Detailed description

There has been no data on effect of Bifidobacterium breve on symptoms of patients with irritable bowel syndrome (IBS). We hypothesized that Bifidobacterium breve is effective on symptoms of IBS patients. IBS patients will be enrolled via advertisement. Any IBS subtypes will not be rejected. They will take either 1.0 g of Bifidobacterium breve 3 times a day or same amount of placebo for 8 weeks. IBS symptoms and allied markers will be checked before, during, and after the administration.

Conditions

• Irritable Bowel Syndrome

Interventions

Type	Name	Description
DRUG	Bifidobacterium breve	1.0 g of Bifidobacterium breve, taking orally, 3 times a day for 8 weeks.
DRUG	Placebo	1.0 g of placebo, taking orally, 3 times a day for 8 weeks.

Timeline

• Start date: 2006-01-01
• Primary completion: 2008-08-01
• Completion: 2008-09-01
• First posted: 2008-08-20
• Last updated: 2008-08-20

Locations

1 site across 1 country: Japan